Aadi Bioscience Says PRECISION1 Tumor-agnostic Trial Unlikely To Meet Regulatory Threshold To Support Accelerated Approval And Will Be Halted
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience announced that its PRECISION1 trial is unlikely to meet the regulatory threshold for accelerated approval and will be halted. The trial's Independent Data Monitoring Committee found it unlikely to exceed the necessary efficacy threshold. Patients benefiting from nab-sirolimus can transition to an expanded access protocol.
August 20, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aadi Bioscience's PRECISION1 trial is halted due to not meeting the efficacy threshold for accelerated approval. This could impact investor confidence and the company's stock price negatively in the short term.
The halting of the PRECISION1 trial indicates a setback in Aadi Bioscience's drug development pipeline, which is critical for future growth and revenue. This news is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100